Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.
Neal D Shore, Paul Sieber, Leanne Schimke, Adam Perzin, Scott Olsen
Index: Urol. Nurs. 33(5) , 236-44, 248, (2013)
Full Text: HTML
Abstract
This multicenter, randomized, crossover, open-label study (ClinicalTrials.gov identifier: NCT01161563) assessed patients'and clinicians'perceptions of injection site tolerability and adverse events following the intramuscular injection of triptorelin pamoate or subcutaneous injection of leuprolide acetate in 107 male, patients with advanced prostate cancer.
Related Compounds
Related Articles:
2014-05-01
[Am. J. Physiol. Regul. Integr. Comp. Physiol. 306(9) , R627-35, (2014)]
2013-03-01
[Med. Oncol. 30(1) , 354, (2013)]
2012-01-01
[JSLS 16(4) , 537-41, (2012)]
2013-12-01
[P. R. Health Sci. J. 32(4) , 200-2, (2013)]
2013-01-01
[Eur. J. Gynaecol. Oncol. 34(3) , 278-9, (2013)]